Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
VSY Biotechnology Appoints Dr. Christian Bach MD
VSY Biotechnology GmbH, a global leader in ophthalmic innovation and research, has announced the appointment of Dr. Christian Bach as the new Managing Director, effective November 1, 2024. Extensive Experience in Medical Devices Dr. Bach brings over 25 years of…
Researchers Find 101 Genetic Links to Cataracts
In the largest genetic study on cataracts to date, researchers from QIMR Berghofer Medical Research Institute have identified 101 genetic regions associated with an increased risk of developing cataracts. This groundbreaking study analyzed DNA from over 950,000 individuals, providing significant…
ESCRS 2024 Exclusive Insights: iNovation Day in Focus
The European Society of Cataract and Refractive Surgeons (ESCRS) is gearing up for an innovative event with its iNovation® Day in Barcelona, Spain, on Friday 6 September 2024 at the Fira Barcelona Gran Via. Scheduled to be held prior to…
Rayner Recalls RayOne Preloaded Hydrophilic IOLs I OBN
According to a notice published by the FDA on July 6, Rayner has issued a letter to recall its RayOne Preloaded Hydrophilic Acrylic IOL Injection Systems containing one MICS injection system with Intraocular Lens. The reason behind this was that…
Bimekizumab Reduces Uveitis Incidence in axSpA Patients
The study led by Matthew A. Brown, Genomics England, London, United Kingdom, and Martin Rudwaleit, Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany. Patients with axial spondyloarthritis (axSpA) treated with bimekizumab exhibited a markedly lower incidence of uveitis compared to those receiving…
Ocular Side Effects Linked to Ovarian Cancer Drug
A recent study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago has identified significant ocular side effects associated with mirvetuximab soravtansine (Elahere), a drug approved for ovarian cancer treatment. The research, conducted by Stanford University, highlights the…
ANX007 Protects Vision in Dry AMD – AAO 2024
A new investigational drug, ANX007, offers hope for the millions of people suffering from geographic atrophy, a severe form of dry age-related macular degeneration (AMD). The drug’s potential to reduce vision loss and protect essential retinal structures was highlighted at…
Long-Term Antiviral Therapy for Ocular Shingles
A new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania and the NYU Grossman School of Medicine suggests that taking an antiviral medication for a year can help prevent vision loss caused by…
OSA 2024 Winners Highlight Innovations in Ophthalmology
VSY Biotechnology GmbH, a global leader in ophthalmic innovation and research, handed the prestigious Ophthalmology Star Awards 2024 (OSA) to its owners during the Satellite Symposium at the ESCRS 2024 Congress in Barcelona. The awards, which were personally presented to…
New Drug Targets for Inherited Retinal Diseases Identified
An international team of researchers has discovered new drug targets for inherited retinal diseases, such as retinitis pigmentosa (RP). Using advanced proteomics, they identified common critical pathways in different disease models, offering hope for broad-spectrum treatments. Key Findings in Retinitis…